Biotech

Biotech Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Takeaways: Winners, snoozers, the China question, and the art of cancer care

The Readout Elaine Chen

STAT Plus: Operation Warp Speed but for rare disease

Adam's Take Adam Feuerstein

STAT Plus: Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug

Biotech Jason Mast

STAT Plus: Illumina board agrees to spin off Grail, as divestment plans proceed

Biotech Matthew Herper, Adam Feuerstein, and Angus Chen

STAT Plus: ASCO Daily Recap: A CAR-T advance, money talk, and tossing the cancer treatment ‘sandwich’

Biotech Angus Chen

STAT Plus: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial

The Readout Meghana Keshavan

STAT Plus: Can AstraZeneca make good on its promise?

Biotech Matthew Herper

STAT Plus: Delfi Diagnostics announces key data, study design for its liquid biopsy test

Biotech Elaine Chen

STAT Plus: Structure Therapeutics oral GLP-1 drug led to weight loss in two studies

Biotech Adam Feuerstein

STAT Plus: Agios drug reduces blood transfusions in patients with beta-thalassemia, study shows

Biotech Matthew Herper

STAT Plus: ASCO24: AstraZeneca won cancer’s big meeting — again. Will that help it fulfill its $80 billion ambition?

Biotech Jason Mast

STAT Plus: Intellia’s CRISPR-based treatment dramatically reduced patients’ swelling attacks in small trial

Biotech Adam Feuerstein

STAT Plus: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment

Pharma Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug

Biotech Elaine Chen

STAT Plus: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone

Biotech Adam Feuerstein

STAT Plus: With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment

Biotech Helen Branswell

STAT Plus: FDA approves Moderna’s RSV vaccine, its second licensed product

The Readout Meghana Keshavan

STAT Plus: The surprising outperformance of a new drug against existing competitors, and other biotech updates

Biotech Matthew Herper

STAT Plus: For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Biotech Jonathan Wosen

STAT Plus: Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials

Biotech Jason Mast

STAT Plus: Ultragenyx gene therapy for rare liver ailment succeeds in late-stage trial

Adam's Take Adam Feuerstein

STAT Plus: Did Sarepta Therapeutics earn $4 billion from exon-skipping drugs that don’t work?

The Readout Elaine Chen

STAT Plus: Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week

Biotech Adam Feuerstein

STAT Plus: Biohaven protein-degrader drug falls short of investor expectations in early-study test

The Readout Elaine Chen

STAT Plus: Wegovy linked to lower risk of alcohol use disorder in real-world study

The Readout Meghana Keshavan

STAT Plus: Biotech’s most interesting fundraisings from the last week

Biotech Andrew Joseph

STAT Plus: Airway disease drug from Insmed succeeds in one of the year’s most anticipated trials

Biotech Adam Feuerstein

STAT Plus: Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer

Biotech Andrew Joseph

STAT Plus: Japanese conglomerate to buy Calliditas Therapeutics, maker of a kidney disease drug